How the US FDA “fully approved” the Pfizer vaccine while still excluding product liability.
How can the US FDA “fully approve” the Pfizer covid vaccine without requiring product liability? As US biosafety expert Dr. Meryl Nass revealed, they simply split the Pfizer vaccine into two products: a branded product (“Comirnaty”), which received a full market license but is currently unavailable in the US (due to “insufficient stocks”); and an unbranded product (“Pfizer/Biontech vaccine”), which is widely available in the US but remains under the existing Emergency Use Authorization (EUA).
The result: they use the unavailable branded product to justify politically motivated vaccination mandates, but they may then deliver the unbranded product to avoid any liability for vaccine injuries (there is no liability under EUA, but there is full liability under a market license).
Dr. Meryl Nass notes that citizens pressured to take this vaccine against their will due to a federal, corporate or school mandate may insist on receiving the (unavailable) licensed product that comes with full liability in case of vaccine injury. For children aged 12 to 15 and for people soon requiring a “booster shot” (due to waning vaccine protection), the FDA hasn’t yet licensed any product.
To learn more about possible covid vaccine injuries, see the updated SPR Covid Vaccine Adverse Events overview. In the US alone, covid vaccines may already have killed or severely injured tens of thousands of people, including people at low risk of severe covid.
As a side note, former FDA Commissioner Scott Gottlieb happens to be a Pfizer board member.
Update: According to the Washington Post, the liability situation is even worse: even the FDA-approved, branded Pfizer vaccine is largely exempt from any product liability, as the product is shielded by the “Public Readiness and Emergency Preparedness Act” (PREP Act).
- The global “vaccine passport” agenda
- Covid vaccines: A shot in the dark?
- Vaccines: Successes and Controversies